Although the primary composite outcome did not reach statistical significance (HR 0.62, 95% CI 0.17–2.17), participants treated with dapagliflozin had a 26.1% reduction in albuminuria compared with 9.9% with placebo, which persisted after a year.
← all excerpts
Sodium glucose co-transporter 2 inhibitors in the treatment of glomerular diseases: a <i>CKJ</i> controversy.
3
—
—
The sentences
The secondary analyses of glomerular disease in EMPA-KIDNEY showed that the benefit of the primary composite outcome or any progression of kidney disease was of borderline significance.
Both dapagliflozin and empagliflozin showed a trend towards a lower rate of eGFR decline as a chronic slope, without reaching statistical significance.